secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001193125-25-032804
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics appoints Anil Singhal to Board; Derek DiRocco to resign at 2025 annual meeting
--------------------------------------------------------------------------------

- Derek DiRocco, M.D. resigns from Board, effective at 2025 annual meeting; no disagreement cited.
- Anil Singhal, Ph.D. appointed as Class I director, effective Feb 19, 2025; joins Audit Committee.
- Dr. Singhal has >30 years biopharma R&D experience; currently President & CEO of Trishula Therapeutics.
- Dr. Singhal receives annual cash comp of $40,000 + $7,500 for Audit Committee; option for 45,000 shares at $1.40, vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/0001193125-25-032804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312525032804/d935677d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-032804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer